why choose us

First received: March 15, 2025

Clinical Trial: Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Intraocular Inflammation

Study Type: OBSERVATIONAL


Official Title: Real-life Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy

Brief Summary: Faricimab (Vabysmo®), a novel pharmaceutical agent is a promising treatment for age-related macular degeneration and diabetic macular edema due to its dual mechanism of action, targeting both the VEGF and angiopoietin-2 (Ang-2) pathways, offering potential benefits in improving visual outcomes and reducing treatment burdens.The phase 3 TENAYA and LUCERNE clinical trials have demonstrated its efficacy and safety profile, leading to regulatory approval and increasing use in clinical practice.However, as with any new…

Read more